Renalytix plc
("Renalytix" or the
"Company")
Director/PDMR share purchase
LONDON and NEW YORK, 20 December 2024
- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), which
is commercialising the only FDA-approved and Medicare reimbursed
prognostic test to support early-stage risk assessment for chronic
kidney disease, announces that Fergus
Fleming, Chief Technology Officer and
Executive Director, has today bought 25,000 ordinary shares of
£0.0025 each ("Ordinary Shares") in the Company at a price of
£0.0975 per Ordinary Share.
Following this transaction, Fergus
Fleming is interested in 594,481
Ordinary Shares representing 0.18% of the issued
share capital of the Company.
For further information,
please contact:
|
Renalytix plc
|
www.renalytix.com
|
|
James McCullough, CEO
|
Via
Walbrook PR
|
|
|
|
|
Stifel (Nominated Adviser and Joint Broker)
|
Tel: 020
7710 7600
|
|
Nicholas Moore / Nick Harland / Ben
Good
|
|
|
|
|
|
Oberon Capital
(Joint Broker)
|
Tel: 020
3179 5300
|
|
Mike Seabrook / Nick Lovering
|
|
|
|
|
|
Walbrook PR Limited
|
Tel: 020
7933 8780 or renalytix@walbrookpr.com
|
|
Paul McManus / Alice Woodings
|
Mob: 07980 541 893 / 07407
804 654
|
|
|
|
|
CapComm Partners
|
|
|
Peter DeNardo
|
Tel:
415-389-6400 or investors@renalytix.com
|
About
Renalytix
Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial
intelligence-enabled in
vitro diagnostics company, focused on optimizing clinical
management of kidney disease to drive improved patient outcomes.
Renalytix has received FDA approval and Medicare reimbursement for
kidneyintelX.dkd which is
now offered commercially in the United States.
Unrecognized and uncontrolled kidney disease remains
one of the largest barriers to controlling cost and suffering in
the United States and the United Kingdom's medical system,
affecting over 14 million and 8 million people, respectively. After
five years of development and clinical validation, kidneyintelX.dkd is the only
FDA-approved and Medicare reimbursed prognostic tool capable of
understanding a patient's risk with kidney disease early where
treatment has maximal effect. kidneyintelX.dkd is now being deployed
across large physician group practices and health systems in select
regions of the United States.
The over 10,000 patients that have been tested by
kidneyintelX.dkd have
produced a substantial body of real-world performance data. In
patient populations where kidneyintelX.dkd has been deployed, a
demonstrated and significant increase in diagnosis, prognosis, and
treatment rates have been recorded. kidneyintelX.dkd now has full
reimbursement established by Medicare, the largest insurance payer
in the United States, at $950 per reportable result. kidneyintelX.dkd is also recommended
for use in the international chronic kidney disease clinical
guidelines (KDIGO).
Notification and public disclosure of
transactions by persons discharging managerial responsibilities and
persons closely associated with them
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Fergus Fleming
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Technology Officer &
Executive Director
|
|
b)
|
Initial notification
/Amendment
|
Initial Notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Renalytix plc
|
|
b)
|
LEI
|
213800NTOH3FK3WER551
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Ordinary shares of £0.0025
each
|
|
|
|
|
Identification code
|
GB00BYWL4Y04
|
|
|
|
|
b)
|
Nature of the transaction
|
Purchase of Ordinary Shares
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
£0.0975
|
25,000
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
- Aggregated volume
|
25,000
|
|
- Price
|
£0.0975
|
|
|
|
|
e)
|
Date of the transaction
|
20 December 2024
|
|
f)
|
Place of the transaction
|
London Stock Exchange, AIM
|
